New drug combo aims to wipe out rare blood cancer
NCT ID NCT03410875
Summary
This study is testing whether a combination of two drugs, vemurafenib (a pill) and obinutuzumab (an infusion), can effectively treat people newly diagnosed with hairy cell leukemia, a rare blood cancer. The goal is to see if this treatment can lead to a complete remission, meaning no detectable cancer after treatment. The study will enroll up to 30 adults who have not had any prior therapy for their leukemia.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LEUKEMIA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Dana Farber Cancer Institute
Boston, Massachusetts, 02115, United States
-
Memorial Sloan Kettering Bergen (Limited Protocol Activities)
Montvale, New Jersey, 07645, United States
-
Memorial Sloan Kettering Cancer Center
New York, New York, 10021, United States
-
Memorial Sloan Kettering Cancer Center @ Commack (Limited Protocol Activities)
Commack, New York, 11725, United States
-
Memorial Sloan Kettering Monmouth (Limited Protocol Activities)
Middletown, New Jersey, 07748, United States
-
Memorial Sloan Kettering Nassau (Limited Protocol Activities)
Uniondale, New York, 11553, United States
-
Memorial Sloan Kettering Westchester (Limited Protocol Activities)
Harrison, New York, 10604, United States
-
Memorial Sloan Kettering at Basking Ridge
Basking Ridge, New Jersey, 07920, United States
-
Yale University
New Haven, Connecticut, 06511, United States
Conditions
Explore the condition pages connected to this study.